Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626671 | 0.98 | TSHR (0.38) | TSHRTDP1EPHX2ALDH1A1GAA | |
| SCHEMBL15456626 | 0.81 | TSHR (0.41) | TSHRTDP1EPHX2ALDH1A1GAA | |
| SCHEMBL939773 | 0.75 | ALDH1A1 (0.47) | TSHRALDH1A1GAASMN1; SMN2 | |
| SCHEMBL3394048 | 0.75 | ALDH1A1 (0.51) | TSHRTDP1EPHX2ALDH1A1GAA | |
| SCHEMBL5713252 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL612325 | 0.73 | ALDH1A1 (0.50) | TSHRTDP1EPHX2ALDH1A1GAA | |
| SCHEMBL11371842 | 0.73 | TSHR (0.40) | TSHRTDP1EPHX2ALDH1A1GAA | |
| SCHEMBL173835 | 0.72 | — | — | |
| SCHEMBL7825503 | 0.71 | ALDH1A1 (0.38) | TSHRTDP1EPHX2ALDH1A1GAA | |
| SCHEMBL594992 | 0.71 | TSHR (0.46) | TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646612-B1 | PROCESSES FOR PREPARING MONTELUKAST SODIUM | TEVA PHARMA (IL) | 2009-07-01 | — | — | EP | claimed |
| US-7547787-B2 | Processes for preparing montelukast sodium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-06-16 | — | — | US | claimed |
| JP-2007532686-A | — | — | 2007-11-15 | — | — | JP | claimed |
| EP-1646612-A1 | PROCESSES FOR PREPARING MONTELUKAST SODIUM | Teva Pharmaceutical Industries Ltd (IL) | 2006-04-19 | — | — | EP | claimed |
| US-20050256156-A1 | Processes for preparing montelukast sodium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-17 | — | — | US | claimed |
| WO-2005105751-A1 | PROCESSES FOR PREPARING MONTELUKAST SODIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| WO-2011004298-A1 | MONTELUKAST HEXAMETHYLENEDIAMINE SALT AND ITS USE FOR THE PREPARATION OF MONTELUKAST SODIUM | ALEMBIC LIMITED (IN) | 2011-01-13 | — | — | WO | disclosed |
| WO-2009138993-A1 | A PROCESS FOR PREPARATION OF MONTELUKAST SODIUM SALT | MACLEODS PHARMACEUTICALS LIMITED (IN) | 2009-11-19 | — | — | WO | disclosed |
| EP-1646612-B1 | PROCESSES FOR PREPARING MONTELUKAST SODIUM | TEVA PHARMA (IL) | 2009-07-01 | — | — | EP | disclosed |
| US-7547787-B2 | Processes for preparing montelukast sodium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-06-16 | — | — | US | disclosed |
| US-7528254-B2 | Process for preparing montelukast and salts thereof | CHEMAGIS LTD. (IL) | 2009-05-05 | — | — | US | disclosed |
| EP-2046750-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST | PLIVA HRVATSKA d.o.o. (HR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008009970-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST | PLIVA HRVATSKA D.O.O. (HR) | 2008-01-24 | — | — | WO | disclosed |
| US-20070208178-A1 | Reacting the side-chain precursor 1-(mercaptomethyl)cyclopropaneacetic acid (not an ester) with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-vinylphenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a basic solvent mixture; forming an amine salt; and exchanging the amine cation with sodium; 99.5+% pure | CHEMAGIS LTD. (IL) | 2007-09-06 | — | — | US | disclosed |
| WO-2007096889-A2 | PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | CHEMAGIS LTD. (IL) | 2007-08-30 | — | — | WO | disclosed |
| EP-1646612-A1 | PROCESSES FOR PREPARING MONTELUKAST SODIUM | Teva Pharmaceutical Industries Ltd (IL) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256156-A1 | Processes for preparing montelukast sodium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-17 | — | — | US | disclosed |
| WO-2005105751-A1 | PROCESSES FOR PREPARING MONTELUKAST SODIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208178-A1 | Reacting the side-chain precursor 1-(mercaptomethyl)cyclopropaneacetic acid (not an ester) with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-vinylphenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a basic solvent mixture; forming an amine salt; and exchanging the amine cation with sodium; 99.5+% pure | CYSLTR2, MPST, CMA1 | TSHR 4337/4885TDP1 4777/4885EPHX2 1613/4885 |
| US-20050256156-A1 | Processes for preparing montelukast sodium | CMA1, LTC4S, PRSS3 | TSHR 4243/4885TDP1 4763/4885EPHX2 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.